Effect upon the human myometrium during early pregnancy of prostaglandin E2 and its analogue 16-phenoxy-omega-17,18,19,20-tetranor-PGE2 methyl sulfonylamide.
A quantitative determination of the pharmacological effect of the prostaglandin analogue 16-phenoxy-omega-17,18,19,20-tetranor-PGE2 methyl sulfonylamide (16-phenoxy-PGE2) and the natural prostaglandin E2 has been made in vivo upon the human myometrium during early pregnancy. The method for the investigation, hysterometry, is based upon the concept that mechanical distension of smooth muscle induces contraction. The contractile response was recorded under basic conditions and during intravenous infusion of the active agent. It was found that the analogue had a 'potency' similar to or slightly more pronounced than the natural prostaglandin E2 when the comparison was made on a microgram basis.
Rydnert
J
J
D000328:Adult; D015232:Dinoprostone / Q000031:analogs & derivatives; D004958:Estradiol / Q000097:blood; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D009215:Myometrium / Q000187:drug effects / Q000502:physiology*; D011247:Pregnancy / Q000502:physiology*; D011261:Pregnancy Trimester, First; D011374:Progesterone / Q000097:blood; D011458:Prostaglandins E / Q000008:administration & dosage / Q000494:pharmacology*; D011459:Prostaglandins E, Synthetic / Q000008:administration & dosage / Q000494:pharmacology*; D014590:Uterine Contraction / Q000187:drug effects*
D011458:Prostaglandins E; D011459:Prostaglandins E, Synthetic; D011374:Progesterone; D004958:Estradiol; C016767:sulprostone; D015232:Dinoprostone